Long-term Administration of High Doses of Transdermal Buprenorphine in Cancer Patients with Severe Neuropathic Pain

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Dec 18

PMID 26675083

Citations 3

Authors

Wojciech Leppert

Grzegorz Kowalski

Affiliations

Soon will be listed here.

Abstract

Background: Buprenorphine is often administered by the transdermal route (transdermal buprenorphine [TB]) in cancer patients with severe neuropathic pain. However, high doses of TB of 140 µg/h are rarely used.

Patients And Methods: Three cancer patients with severe neuropathic Numeric Rating Scale (NRS) pain scores of 8-10 who were successfully treated with high doses of TB up to 140 µg/h along with other opioids and adjuvant analgesics.

Results: TB was administered for a long period of follow-up (9 months to 4 years, including 34-261 days of treatment with the dose of 140 µg/h), which allowed achievement of satisfactory analgesia (NRS 3-5) and good treatment tolerance. In all three patients, TB dose was gradually titrated from 35 to 140 µg/h, and all patients used morphine at least for some time for breakthrough and background pain management along with adjuvant analgesics. Two patients continued the treatment with TB until the end of life, and one patient is still receiving the treatment.

Conclusion: TB at doses of up to 140 µg/h in cancer patients with severe neuropathic pain seems to be effective and safe in combination with other opioids and with adjuvant analgesics, and may significantly improve patients' quality of life. Clinical studies may explore higher than maximal 140 µg/h TB doses recommended by a manufacturer, and also in combination with other opioids and adjuvant analgesics.

Citing Articles

Opioid Analgesia and Opioid-Induced Adverse Effects: A Review.

Paul A, Smith C, Rahmatullah M, Nissapatorn V, Wilairatana P, Spetea M Pharmaceuticals (Basel). 2021; 14(11).

PMID: 34832873 PMC: 8620360. DOI: 10.3390/ph14111091.

Rectal enema of bupivacaine in cancer patients with tenesmus pain - case series.

Kowalski G, Leppert W, Adamski M, Szkutnik-Fiedler D, Baczyk E, Domagalska M J Pain Res. 2019; 12:1847-1854.

PMID: 31354333 PMC: 6578571. DOI: 10.2147/JPR.S192308.

Multidimensional Treatment of Cancer Pain.

Liu W, Zheng Z, Tan K, Meredith G Curr Oncol Rep. 2017; 19(2):10.

PMID: 28220448 DOI: 10.1007/s11912-017-0570-0.

References

Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M . Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005; 118(1-2):15-22. DOI: 10.1016/j.pain.2005.06.030. View

Przeklasa-Muszynska A, Dobrogowski J . Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland. Curr Med Res Opin. 2011; 27(6):1109-17. DOI: 10.1185/03007995.2011.569017. View

Sittl R . Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 2006; 20 Suppl 1:s25-30. View

Kogel B, Christoph T, Strassburger W, Friderichs E . Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005; 9(5):599-611. DOI: 10.1016/j.ejpain.2005.02.002. View

Clement P, Beuselinck B, Van Beek K, Georgette Mertens P, Cornelissen P, Menten J . The use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: a case study. Case Rep Oncol. 2013; 6(1):169-73. PMC: 3636962. DOI: 10.1159/000349917. View

Gastmeier K, Freye E . [High-dose buprenorphine for outpatient palliative pain therapy]. Schmerz. 2008; 23(2):180-6. DOI: 10.1007/s00482-008-0742-9. View

Caraceni A, Hanks G, Kaasa S, Bennett M, Brunelli C, Cherny N . Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2):e58-68. DOI: 10.1016/S1470-2045(12)70040-2. View

Szczudlik A, Dobrogowski J, Wordliczek J, Stepien A, Krajnik M, Leppert W . Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society - Part Two. Neurol Neurochir Pol. 2014; 48(6):423-35. DOI: 10.1016/j.pjnns.2014.11.002. View

Kress H . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2008; 13(3):219-30. DOI: 10.1016/j.ejpain.2008.04.011. View

10.

Wang J, Cai B, Huang D, Yang S, Guo L . Decreased analgesic effect of morphine, but not buprenorphine, in patients with advanced P-glycoprotein(+) cancers. Pharmacol Rep. 2012; 64(4):870-7. DOI: 10.1016/s1734-1140(12)70881-2. View

11.

Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E . Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol. 2005; 507(1-3):87-98. DOI: 10.1016/j.ejphar.2004.11.052. View

12.

Davis M . Buprenorphine in cancer pain. Support Care Cancer. 2005; 13(11):878-87. DOI: 10.1007/s00520-005-0849-9. View

13.

Johnson R, Fudala P, Payne R . Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005; 29(3):297-326. DOI: 10.1016/j.jpainsymman.2004.07.005. View

14.

Bulka A, Kouya P, Bottiger Y, Svensson J, Xu X, Wiesenfeld-Hallin Z . Comparison of the antinociceptive effect of morphine, methadone, buprenorphine and codeine in two substrains of Sprague-Dawley rats. Eur J Pharmacol. 2004; 492(1):27-34. DOI: 10.1016/j.ejphar.2004.03.041. View

15.

Walsh S, Preston K, Stitzer M, Cone E, Bigelow G . Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994; 55(5):569-80. DOI: 10.1038/clpt.1994.71. View

16.

Mercadante S, Ferrera P, Villari P . Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2006; 15(4):441-4. DOI: 10.1007/s00520-006-0169-8. View

17.

Griessinger N, Sittl R, Likar R . Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005; 21(8):1147-56. DOI: 10.1185/030079905X53315. View

18.

Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L . Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006; 32(2):175-9. DOI: 10.1016/j.jpainsymman.2006.01.013. View

19.

Leppert W, Kowalski G . Methadone as an additional opioid for a cancer patient with severe neuropathic and bone pain not responsive to other opioids and adjuvant analgesics. J Palliat Care. 2013; 29(2):119-21. View

20.

Belcheva M, Barg J, McHale R, Dawn S, Ho M, Ignatova E . Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol Pharmacol. 1993; 44(1):173-9. PMC: 2516495. View